LPL Receptor

LPL Receptor製品

• All (30)
• LPL Receptor阻害剤 (1)
• LPL Receptor抗体(1)
• LPL Receptor活性剤(1)
• LPL Receptor拮抗剤(11)
• LPL Receptor作動薬(6)
• LPL Receptorモジュレータ(3)
• 新製品

製品コード	製品名称	製品説明	文献中Selleckの製品使用例	お客様のフィードバック
S5002	Fingolimod (FTY720) Hydrochloride	Fingolimod (FTY720, Fingolimod Hydrochloride) HCl is a S1P antagonist with IC50 of 0.033 nM in K562, and NK cells.Please use saline solution rather than PBS for dilutions. PBS may cause precipitation.	Cancer Cell, 2025, S1535-6108(25)00319-8 Nat Commun, 2025, 16(1):9175 Nat Commun, 2025, 16(1):1826
S7177	PF-543 hydrochloride	PF-543 hydrochloride, a novel sphingosine-competitive inhibitor of SphK1, inhibits SphK1 with IC50 and Ki of 2.0 nM and 3.6 nM, exhibits >100-fold selectivity over the SphK2 isoform. PF-543 hydrochloride induces apoptosis, necrosis, and autophagy.	Cell Death Discov, 2025, 11(1):29 FASEB J, 2025, 39(12):e70768 FASEB J, 2025, 39(12):e70768
S1315	Ki16425	Ki16425 is a competitive, potent and reversible antagonist to LPA1, LPA2 and LPA3 with Ki of 0.34 μM, 6.5 μM and 0.93 μM in RH7777 cell lines, respectively, shows no activity at LPA4, LPA5, LPA6.	Cell Rep, 2024, 43(11):114972 JCI Insight, 2024, 9(24)e178535 Lipids Health Dis, 2024, 23(1):381
S5950	Fingolimod (FTY-720)	Fingolimod (FTY-720) is a sphingosine 1-phosphate receptor modulator used for the treatment of relapsing-remitting multiple sclerosis.	Nat Commun, 2024, 15(1):6970 Ther Adv Neurol Diso, 2024, 17:17562864241300047 Oncol Res, 2023, 31(6):867-875
S7179	Siponimod (BAF312)	BAF312 (Siponimod) is a next-generation S1P receptor modulator, selective for S1P1 and S1P5 receptors with EC50 of 0.39 nM and 0.98 nM, exhibits >1000-fold selectivity over S1P2, S1P3 and S1P4 receptors. Phase 3.	Cell Death Dis, 2025, 16(1):282 Cancers (Basel), 2024, 16(3)574 J Neuroinflammation, 2023, 20(1):35
S7182	JTE 013	JTE 013 is a potent and selective S1P2 antagonist with IC50 of 17.6 nM.	Cell Death Dis, 2025, 16(1):282 Front Pharmacol, 2024, 15:1494210 Cell Res, 2022, 10.1038/s41422-022-00614-0
S7952	Ozanimod	Ozanimod is a selective oral S1P Receptor 1 modulator. Phase 3.	Nat Commun, 2025, 16(1):1826 Front Immunol, 2024, 15:1230735 Front Immunol, 2024, 15:1230735
S8241	Ponesimod (ACT-128800)	Ponesimod (ACT-128800) is an orally active, selective sphingosine-1-phosphate receptor 1 (S1P1) immunomodulator with EC50 of 5.7 nM.	Cancers (Basel), 2024, 16(3)574 EBioMedicine, 2023, 94:104713 Int J Mol Sci, 2022, 23(18)10311
S4578	Tyloxapol	Tyloxapol (Triton WR1339) is a nonionic liquid polymer of the alkyl aryl polyether alcohol type, used as a surfactant to aid liquefaction, removal of mucopurulent and bronchopulmonary secretions. It also blocks plasma lipolytic activity, and thus the breakdown of triglyceride-rich lipoproteins.Tyloxapol can be used to induce animal models of Hyperlipidemia, Atherosclerosis.	iScience, 2022, 25(10):105068 Front Cell Dev Biol, 2022, 10:808140 bioRxiv, 2020, 2020/9/20.4.7.30734
S2906	Ki16198	Ki16198 is the methyl ester of Ki16425, which is a LPA antagonist and inhibits LPA1- and LPA3-induced inositol phosphate production with Ki of 0.34 μM and 0.93 μM, respectively, shows weaker inhibition for LPA2, no activity at LPA4, LPA5, LPA6.	Neurosci Bull, 2016, 32(5):445-54
S8345	ONO-7300243	ONO-7300243 is a novel, potent LPA1(Lysophosphatidic Acid Receptor) antagonist with an IC50 of 160 nM.	Eur J Pharmacol, 2020, 868:172886
S6633	AM 095	AM095 is an antagonist of the LPA type 1 receptor with IC50 values of 0.98 and 0.73 μM for recombinant human and mouse LPA1, respectively.	Gastroenterology, 2022, 162(4):1210-1225
S7180New	SEW 2871	SEW2871 is an orally active, potent, and highly selective agonist of the sphingosine-1-phosphate type 1 receptor (S1P1) with an EC50 of 13.8 nM. It activates ERK, Akt, and Rac signalling pathways and induces S1P1 internalization and recycling.	Cell Death Dis, 2021, 12(11):1050
E2363	Etrasimod(APD334)	Etrasimod(APD334) is a potent, selective and orally available antagonist of the sphingosine-1-phosphate-1 (S1P1) receptor with an EC50 value of 1.88 nM in CHO cells.
S0536	Ibrolipim	Ibrolipim (NO-1886) is an effective lipoprotein lipase (LPL) activator that increases LPL mRNA and LPL activity in adipose tissue, myocardium, and skeletal muscle.
S3534	AM966	AM966 is a high affinity, selective, oral Lysophosphatidic acid receptor 1 (LPA1) antagonist, which can inhibit LPA-stimulated intracellular calcium release (IC50=17 nM, by Ca flux assay).
S6552	CYM5541	CYM5541 (ML249) is a selective, allosteric agonist of S1P3 with an EC50 of between 72 and 132 nM and exhibits exquisite selectivity over other S1P receptor subtypes in vitro: S1P1 EC50 > 10 μM, S1P2 EC50 > 50 μM, S1P4 EC50 > 50 μM, and S1P5 EC50 > 25 μM.	Brain Behav Immun, 2024, 124:205-217
E1999	Sphingosine-1-phosphate	Sphingosine-1-phosphate (S1P) is an agonist of S1P1-5 receptors and a ligand toGPR3, GPR6 and GPR12. It enhances GPR3-, GPR6-, and GPR12-mediated intracellular Ca²⁺ mobilization and regulates essential cellular processes such as proliferation, migration, cytoskeletal organization, adherens junction assembly, and morphogenesis.
S3572	BMS-986020	BMS-986020 (AM152, AP-3152 free acid) is a potent and selective antagonist of lysophosphatidic acid receptor 1 (LPA1). BMS-986020 inhibits bile acid and phospholipid transporters with IC50 of 4.8 μM, 6.2 μM, and 7.5 μM for BSEP, MRP4, and MDR3, respectively. BMS-986020 has the potential for the treatment of idiopathic pulmonary fibrosis (IPF).
E7476New	TY-52156	TY - 52156は、Ki値が110 nMである強力かつ選択的なS1P3受容体拮抗薬です。
S4462	CYM-5520	CYM-5520 is a highly selective sphingosine-1-phosphate receptor 2 (S1PR2) agonist with an EC50 of 0.48 µM and does not activate other S1P receptors.	Front Pharmacol, 2024, 15:1494210
S3412	CYM50308	CYM50308 (ML248) is a potent and selective S1P4 receptor agonist with an EC50 of 56 nM.
S7181	W146	W146 is a selective antagonist of sphingosine-1-phosphate receptor 1 (S1PR1) with an EC50 value of 398 nM. It may exhibit potential clinical applications in multiple sclerosis, coronary artery disease, diabetes, and cancer treatment.
A2345	Sonepcizumab (Anti-Sphingosine-1-phosphate)	Sonepcizumab (Anti-Sphingosine-1-phosphate) is a humanized monoclonal antibody directed against sphingosine 1-phosphate (S1P) with potential antiangiogenic and antineoplastic activities. MW : 145.5 KD.
S7179	Siponimod (BAF312)	BAF312 (Siponimod) is a next-generation S1P receptor modulator, selective for S1P1 and S1P5 receptors with EC50 of 0.39 nM and 0.98 nM, exhibits >1000-fold selectivity over S1P2, S1P3 and S1P4 receptors. Phase 3.	Cell Death Dis, 2025, 16(1):282 Cancers (Basel), 2024, 16(3)574 J Neuroinflammation, 2023, 20(1):35
S7180New	SEW 2871	SEW2871 is an orally active, potent, and highly selective agonist of the sphingosine-1-phosphate type 1 receptor (S1P1) with an EC50 of 13.8 nM. It activates ERK, Akt, and Rac signalling pathways and induces S1P1 internalization and recycling.	Cell Death Dis, 2021, 12(11):1050
S6552	CYM5541	CYM5541 (ML249) is a selective, allosteric agonist of S1P3 with an EC50 of between 72 and 132 nM and exhibits exquisite selectivity over other S1P receptor subtypes in vitro: S1P1 EC50 > 10 μM, S1P2 EC50 > 50 μM, S1P4 EC50 > 50 μM, and S1P5 EC50 > 25 μM.	Brain Behav Immun, 2024, 124:205-217
E1999	Sphingosine-1-phosphate	Sphingosine-1-phosphate (S1P) is an agonist of S1P1-5 receptors and a ligand toGPR3, GPR6 and GPR12. It enhances GPR3-, GPR6-, and GPR12-mediated intracellular Ca²⁺ mobilization and regulates essential cellular processes such as proliferation, migration, cytoskeletal organization, adherens junction assembly, and morphogenesis.
S4462	CYM-5520	CYM-5520 is a highly selective sphingosine-1-phosphate receptor 2 (S1PR2) agonist with an EC50 of 0.48 µM and does not activate other S1P receptors.	Front Pharmacol, 2024, 15:1494210
S3412	CYM50308	CYM50308 (ML248) is a potent and selective S1P4 receptor agonist with an EC50 of 56 nM.
S7177	PF-543 hydrochloride	PF-543 hydrochloride, a novel sphingosine-competitive inhibitor of SphK1, inhibits SphK1 with IC50 and Ki of 2.0 nM and 3.6 nM, exhibits >100-fold selectivity over the SphK2 isoform. PF-543 hydrochloride induces apoptosis, necrosis, and autophagy.	Cell Death Discov, 2025, 11(1):29 FASEB J, 2025, 39(12):e70768 FASEB J, 2025, 39(12):e70768
A2345	Sonepcizumab (Anti-Sphingosine-1-phosphate)	Sonepcizumab (Anti-Sphingosine-1-phosphate) is a humanized monoclonal antibody directed against sphingosine 1-phosphate (S1P) with potential antiangiogenic and antineoplastic activities. MW : 145.5 KD.
S0536	Ibrolipim	Ibrolipim (NO-1886) is an effective lipoprotein lipase (LPL) activator that increases LPL mRNA and LPL activity in adipose tissue, myocardium, and skeletal muscle.
S5002	Fingolimod (FTY720) Hydrochloride	Fingolimod (FTY720, Fingolimod Hydrochloride) HCl is a S1P antagonist with IC50 of 0.033 nM in K562, and NK cells.Please use saline solution rather than PBS for dilutions. PBS may cause precipitation.	Cancer Cell, 2025, S1535-6108(25)00319-8 Nat Commun, 2025, 16(1):9175 Nat Commun, 2025, 16(1):1826
S1315	Ki16425	Ki16425 is a competitive, potent and reversible antagonist to LPA1, LPA2 and LPA3 with Ki of 0.34 μM, 6.5 μM and 0.93 μM in RH7777 cell lines, respectively, shows no activity at LPA4, LPA5, LPA6.	Cell Rep, 2024, 43(11):114972 JCI Insight, 2024, 9(24)e178535 Lipids Health Dis, 2024, 23(1):381
S7182	JTE 013	JTE 013 is a potent and selective S1P2 antagonist with IC50 of 17.6 nM.	Cell Death Dis, 2025, 16(1):282 Front Pharmacol, 2024, 15:1494210 Cell Res, 2022, 10.1038/s41422-022-00614-0
S2906	Ki16198	Ki16198 is the methyl ester of Ki16425, which is a LPA antagonist and inhibits LPA1- and LPA3-induced inositol phosphate production with Ki of 0.34 μM and 0.93 μM, respectively, shows weaker inhibition for LPA2, no activity at LPA4, LPA5, LPA6.	Neurosci Bull, 2016, 32(5):445-54
S8345	ONO-7300243	ONO-7300243 is a novel, potent LPA1(Lysophosphatidic Acid Receptor) antagonist with an IC50 of 160 nM.	Eur J Pharmacol, 2020, 868:172886
S6633	AM 095	AM095 is an antagonist of the LPA type 1 receptor with IC50 values of 0.98 and 0.73 μM for recombinant human and mouse LPA1, respectively.	Gastroenterology, 2022, 162(4):1210-1225
E2363	Etrasimod(APD334)	Etrasimod(APD334) is a potent, selective and orally available antagonist of the sphingosine-1-phosphate-1 (S1P1) receptor with an EC50 value of 1.88 nM in CHO cells.
S3534	AM966	AM966 is a high affinity, selective, oral Lysophosphatidic acid receptor 1 (LPA1) antagonist, which can inhibit LPA-stimulated intracellular calcium release (IC50=17 nM, by Ca flux assay).
S3572	BMS-986020	BMS-986020 (AM152, AP-3152 free acid) is a potent and selective antagonist of lysophosphatidic acid receptor 1 (LPA1). BMS-986020 inhibits bile acid and phospholipid transporters with IC50 of 4.8 μM, 6.2 μM, and 7.5 μM for BSEP, MRP4, and MDR3, respectively. BMS-986020 has the potential for the treatment of idiopathic pulmonary fibrosis (IPF).
E7476New	TY-52156	TY - 52156は、Ki値が110 nMである強力かつ選択的なS1P3受容体拮抗薬です。
S7181	W146	W146 is a selective antagonist of sphingosine-1-phosphate receptor 1 (S1PR1) with an EC50 value of 398 nM. It may exhibit potential clinical applications in multiple sclerosis, coronary artery disease, diabetes, and cancer treatment.
S7179	Siponimod (BAF312)	BAF312 (Siponimod) is a next-generation S1P receptor modulator, selective for S1P1 and S1P5 receptors with EC50 of 0.39 nM and 0.98 nM, exhibits >1000-fold selectivity over S1P2, S1P3 and S1P4 receptors. Phase 3.	Cell Death Dis, 2025, 16(1):282 Cancers (Basel), 2024, 16(3)574 J Neuroinflammation, 2023, 20(1):35
S7180New	SEW 2871	SEW2871 is an orally active, potent, and highly selective agonist of the sphingosine-1-phosphate type 1 receptor (S1P1) with an EC50 of 13.8 nM. It activates ERK, Akt, and Rac signalling pathways and induces S1P1 internalization and recycling.	Cell Death Dis, 2021, 12(11):1050
S6552	CYM5541	CYM5541 (ML249) is a selective, allosteric agonist of S1P3 with an EC50 of between 72 and 132 nM and exhibits exquisite selectivity over other S1P receptor subtypes in vitro: S1P1 EC50 > 10 μM, S1P2 EC50 > 50 μM, S1P4 EC50 > 50 μM, and S1P5 EC50 > 25 μM.	Brain Behav Immun, 2024, 124:205-217
E1999	Sphingosine-1-phosphate	Sphingosine-1-phosphate (S1P) is an agonist of S1P1-5 receptors and a ligand toGPR3, GPR6 and GPR12. It enhances GPR3-, GPR6-, and GPR12-mediated intracellular Ca²⁺ mobilization and regulates essential cellular processes such as proliferation, migration, cytoskeletal organization, adherens junction assembly, and morphogenesis.
S4462	CYM-5520	CYM-5520 is a highly selective sphingosine-1-phosphate receptor 2 (S1PR2) agonist with an EC50 of 0.48 µM and does not activate other S1P receptors.	Front Pharmacol, 2024, 15:1494210
S3412	CYM50308	CYM50308 (ML248) is a potent and selective S1P4 receptor agonist with an EC50 of 56 nM.
S5950	Fingolimod (FTY-720)	Fingolimod (FTY-720) is a sphingosine 1-phosphate receptor modulator used for the treatment of relapsing-remitting multiple sclerosis.	Nat Commun, 2024, 15(1):6970 Ther Adv Neurol Diso, 2024, 17:17562864241300047 Oncol Res, 2023, 31(6):867-875
S7952	Ozanimod	Ozanimod is a selective oral S1P Receptor 1 modulator. Phase 3.	Nat Commun, 2025, 16(1):1826 Front Immunol, 2024, 15:1230735 Front Immunol, 2024, 15:1230735
S8241	Ponesimod (ACT-128800)	Ponesimod (ACT-128800) is an orally active, selective sphingosine-1-phosphate receptor 1 (S1P1) immunomodulator with EC50 of 5.7 nM.	Cancers (Basel), 2024, 16(3)574 EBioMedicine, 2023, 94:104713 Int J Mol Sci, 2022, 23(18)10311
S7180New	SEW 2871	SEW2871 is an orally active, potent, and highly selective agonist of the sphingosine-1-phosphate type 1 receptor (S1P1) with an EC50 of 13.8 nM. It activates ERK, Akt, and Rac signalling pathways and induces S1P1 internalization and recycling.	Cell Death Dis, 2021, 12(11):1050
E7476New	TY-52156	TY - 52156は、Ki値が110 nMである強力かつ選択的なS1P3受容体拮抗薬です。
S7180New	SEW 2871	SEW2871 is an orally active, potent, and highly selective agonist of the sphingosine-1-phosphate type 1 receptor (S1P1) with an EC50 of 13.8 nM. It activates ERK, Akt, and Rac signalling pathways and induces S1P1 internalization and recycling.	Cell Death Dis, 2021, 12(11):1050